Featured Question

Treatment selection for patients with metastatic colorectal cancer (mCRC) can be particularly challenging when there is no clear evidence to guide treatment decisions or when the available agents are comparable in efficacy. For example, data reported last year showed that bevacizumab or cetuximab, in combination with either FOLFOXa or FOLFIRIb chemotherapy regimens, yielded similarly effective overall survival outcomes in patients with metastatic CRC and no KRAS mutations. How should one approach treatment planning in cases like that? If patient preference should influence the decisions, how can we ensure that patients are informed well enough to participate in decision-making in a meaningful way?

See The Answer

Get the latest
science delivered
to your inbox

Answers in CME updates are
available in YOUR specialty.

Sign-up Now!

Featured Activities

09-17-2015

Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on Appropriate Patient Selection and Nuances of Clinical Use

Course Director
Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center,
Temple Health
Philadelphia, Pennsylvania

09-11-2015

Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on the Current State of the Science and Implications for Practice

Course Director
Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center,
Temple Health
Philadelphia, Pennsylvania

06-08-2015

Individualized Treatment Selection for Patients With Type 2 Diabetes: Considering the Role of the GLP-1 Receptor Agonists in the Context of Other Therapies

Course Director
Guillermo E. Umpierrez, MD, CDE, FACP, FACE
Emory University
Grady Health System
Atlanta, Georgia

05-13-2015

Challenging Cases in Schizophrenia: Considerations for Individualized Treatment Selection

Course Director
Christoph U. Correll, MD
Hofstra North Shore LIJ School of Medicine
The Zucker Hillside Hospital
Glen Oaks, New York

05-12-2015

Current Perspectives on the Evolving Treatment Landscape in Schizophrenia and Practical Recommendations for Improving Patient Care

Course Director
Christoph U. Correll, MD
Hofstra North Shore LIJ School of Medicine
The Zucker Hillside Hospital
Glen Oaks, New York

05-06-2015

Assessing the Benefits and Limitations of the GLP-1 Receptor Agonists in the Management of Type 2 Diabetes

Course Director
Guillermo E. Umpierrez, MD, CDE, FACP, FACE
Emory University
Grady Health System
Atlanta, Georgia

04-29-2015

Current Perspectives in Management of Hypercholesterolemia: Practical Considerations for Screening and Treatment Selection

Course Director
Peter P. Toth, MD, PhD, FAAFP, FNLA, FICA, FCCP, FAHA, FACC
CGH Medical Center
Sterling, Illinois
University of Illinois
College of Medicine
Peoria, Illinois
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan
Johns Hopkins University
School of Medicine
Baltimore, Maryland

04-27-2015

New and Emerging Treatment Options for Hypercholesterolemia: Evaluating the Characteristics, Benefits, Limitations, and Potential Roles

Course Director
Peter P. Toth, MD, PhD, FAAFP, FNLA, FICA, FCCP, FAHA, FACC
CGH Medical Center
Sterling, Illinois
University of Illinois
College of Medicine
Peoria, Illinois
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan
Johns Hopkins University
School of Medicine
Baltimore, Maryland

04-17-2015

Challenging Cases in Advanced Colorectal Cancer: Considering the Latest Evidence and Patient Preferences as Part of Shared Decision-Making

Course Director
Johanna C. Bendell, MD
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

04-15-2015

Considering the Latest Evidence and Factors to Guide Individualized Treatment Planning in Metastatic Colorectal Cancer

Course Director
Johanna C. Bendell, MD
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee